✦ LIBER ✦

Comments on the FDA draft guidance on biosimilar products

✍ Scribed by Shein-Chung Chow; Laszlo Endrenyi; Peter A. Lachenbruch

Book ID: 115562105
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 87 KB
Volume: 32
Category: Article
ISSN: 0277-6715
DOI: 10.1002/sim.5572

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Meeting on the FDA Draft Guidance on Pat

Meeting on the FDA Draft Guidance on Patient-Reported Outcomes

✍ Amylou C. Dueck; Jeff A. Sloan 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 36 KB

Some statistical considerations on the F

Some statistical considerations on the FDA draft guidance for individual bioequivalence

✍ Francis C. Hsuan 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB 👁 2 views

In December of 1997, the FDA proposed a draft guidance for future in vivo bioequivalence studies. The guidance suggested speciÿc criteria for new drug sponsors to show individual bioequivalence (IBE). The criteria use a mixed-scaling aggregate strategy. It has been generally accepted that, under som

Current regulatory (draft) guidance on c

Current regulatory (draft) guidance on chiral medicinal products: Canada, EEC, Japan, United States

✍ Dr. Adalbert Gerard Rauws; Kees Groen 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 469 KB

FDA issues long-awaited guidance on bron

FDA issues long-awaited guidance on bronchitis exacerbations

✍ Kelly Morris 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 87 KB

Implementing the U.S. FDA guidance on ph

Implementing the U.S. FDA guidance on pharmacogenomic data submissions

✍ Federico Goodsaid; Felix W. Frueh 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 257 KB

PMC55 IMPACT OF THE FDA DRAFT GUIDANCE O

PMC55 IMPACT OF THE FDA DRAFT GUIDANCE ON PATIENT REPORTED OUTCOMES (PRO) LABEL CLAIMS FOR APPROVED DRUG PRODUCTS IN THE US: HAS IT MADE A DIFFERENCE?

✍ M Mordin; M Clark; C Siersma; K Copley-Merriman; A Gnanasakthy 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB